Maturitas
Volume 61, Issue 4 , Pages 345-349 , 20 December 2008

Effects of tibolone and conventional HRT on the expression of estrogen and progesterone receptors in the breast

  • L. Ma

      Affiliations

    • Division for Reproductive Endocrinology, Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden
    • ,
  • M. Hofling

      Affiliations

    • Division of Obstetrics and Gynecology, Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden
    • ,
  • B. Masironi

      Affiliations

    • Division for Reproductive Endocrinology, Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden
    • ,
  • B. von Schoultz

      Affiliations

    • Division of Obstetrics and Gynecology, Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden
    • ,
  • J.M. Cline

      Affiliations

    • Wake Forest University School of Medicine Winston-Salem, NC, USA
    • ,
  • L. Sahlin

      Affiliations

    • Division for Reproductive Endocrinology, Department of Woman and Child Health, Karolinska Institutet, Stockholm, Sweden
    • Corresponding Author InformationCorresponding author at: Division for Reproductive Endocrinology, Department of Woman and Child Health, Q2:08, Karolinska University Hospital - Solna, SE-171 76 Stockholm, Sweden. Tel.: +46 8 51773491; fax: +46 8 51775128.

Received 9 July 2008 ,Revised 12 September 2008 ,Accepted 15 September 2008.

References 

  1. Schairer C, Lubin J, Troisi R, et al. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA. 2000;283:485–491
  2. Gompel A, Siromachkova M, Lombet A, et al. Tibolone actions on normal and breast cancer cells. Eur J Cancer. 2000;36(Suppl 4):S76–S77
  3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  4. Santen RJ, Pinkerton J, McCartney C, Petroni GR. Risk of breast cancer with progestins in combination with estrogen as hormone replacement therapy. J Clin Endocrinol Metab. 2001;86:16–23
  5. Soderqvist G, von Schoultz B. Lessons to be learned from clinical studies on hormones and the breast. Maturitas. 2004;49:90–96
  6. Lundstrom E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol. 2002;186:717–722
  7. Santen R. Menopausal hormone therapies: their effect on mammographic density and breast cancer risk. Gynecol Endocrinol. 2005;21(Suppl 1):12–16
  8. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol. 2001;76:231–238
  9. Kloosterboer HJ. Tissue-selective effects of tibolone on the breast. Maturitas. 2004;49:S5–S15
  10. Christodoulakos GE, Lambrinoudaki IV, Vourtsi AD, et al. Mammographic changes associated with raloxifene and tibolone therapy in postmenopausal women: a prospective study. Menopause. 2002;9:110–116
  11. Bruce D, Rymer J, Robinson J, et al. The long-term effects of tibolone on aortic stiffness and endothelial function. Climacteric. 2005;8:221–229
  12. Reid SE, Murthy MS, Kaufman M, Scanlon EF. Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. Br J Surg. 1996;83:1037–1046
  13. Nilsson S, Makela S, Treuter E, et al. Mechanisms of estrogen action. Physiol Rev. 2001;81:1535–1565
  14. Liu MM, Albanese C, Anderson CM, et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem. 2002;277:24353–24360
  15. Clarke M. Meta-analyses of adjuvant therapies for women with early breast cancer: the Early Breast Cancer Trialists’ Collaborative Group overview. Ann Oncol. 2006;17(Suppl 10):x59–x62
  16. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687–717.
  17. Hofseth LJ, Raafat AM, Osuch JR, et al. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab. 1999;84:4559–4565
  18. Cline JM, Wood CE. Hormonal effects on the mammary gland of postmenopausal nonhuman primates. Breast Dis. 2005;24:59–70
  19. Graham JD, Yager ML, Hill HD, et al. Altered progesterone receptor isoform expression remodels progestin responsiveness of breast cancer cells. Mol Endocrinol. 2005;19:2713–2735
  20. Conneely OM, Lydon JP. Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids. 2000;65:571–577
  21. Isaksson E, Wang H, Sahlin L, et al. Effects of long-term HRT and tamoxifen on the expression of progesterone receptors A and B in breast tissue from surgically postmenopausal cynomolgus macaques. Breast Cancer Res Treat. 2003;79:233–239
  22. Cline JM, Soderqvist G, Register TC, et al. Assessment of hormonally active agents in the reproductive tract of female nonhuman primates. Toxicol Pathol. 2001;29:84–90
  23. Cline JM, Soderqvist G, von Schoultz E, et al. Effects of conjugated estrogens, medroxyprogesterone acetate, and tamoxifen on the mammary glands of macaques. Breast Cancer Res Treat. 1998;48:221–229
  24. Conner P, Christow A, Kersemaekers W, et al. A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolon and continuous combined estrogen–progestogen treatment. Climacteric. 2004;7:50–58
  25. Cline JM, Register TC, Clarkson TB. Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause. 2002;9:422–429
  26. Wang H, Masironi B, Eriksson H, Sahlin L. A comparative study of estrogen receptors alpha and beta in the rat uterus. Biol Reprod. 1999;61:955–964
  27. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419–427
  28. Opatrny L, Dell’Aniello S, Assouline S, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. Bjog. 2008;115:169–175discussion 175
  29. Conner P. Breast response to menopausal hormone therapy—aspects on proliferation, apoptosis and mammographic density. Ann Med. 2007;39:28–41
  30. McDonnell DP, Norris JD. Connections and regulation of the human estrogen receptor. Science. 2002;296:1642–1644
  31. Matthews J, Wihlen B, Tujague M, et al. Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol. 2006;20:534–543
  32. Isaksson E, Wang H, Sahlin L, et al. Expression of estrogen receptors (alpha, beta) and insulin-like growth factor-I in breast tissue from surgically postmenopausal cynomolgus macaques after long-term treatment with HRT and tamoxifen. Breast. 2002;11:295–300
  33. Reed MJ, Kloosterboer HJ. Tibolone: a selective tissue estrogenic activity regulator (STEAR). Maturitas. 2004;48(Suppl 1):S4–6
  34. Tang B, Markiewicz L, Kloosterboer HJ, Gurpide E. Human endometrial 3 beta-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14). J Steroid Biochem Mol Biol. 1993;45:345–351
  35. Punnonen R, Liukko P, Cortes-Prieto J, et al. Multicentre study of effects of Org OD 14 on endometrium, vaginal cytology and cervical mucus in post-menopausal and oophorectomized women. Maturitas. 1984;5:281–286
  36. Genazzani AR, Benedek-Jaszmann LJ, Hart DM, et al. Org OD 14 and the endometrium. Maturitas. 1991;13:243–251
  37. Bundred NJ, Turner LE. Postmenopausal hormone therapy before and after breast cancer: clinical experiences. Maturitas. 2004;49:S22–31
  38. Colacurci N, Mele D, De Franciscis P, et al. Effects of tibolone on the breast. Eur J Obstet Gynecol Reprod Biol. 1998;80:235–238
  39. Ozdemir A, Konus O, Nas T, et al. Mammographic and ultrasonographic study of changes in the breast related to HRT. Int J Gynaecol Obstet. 1999;67:23–32

PII: S0378-5122(08)00252-1

doi: 10.1016/j.maturitas.2008.09.018

Maturitas
Volume 61, Issue 4 , Pages 345-349 , 20 December 2008

Article Tools

* Image Usage & Resolution